IMBiotechnologies Ltd. (IMB) is a privately held Canadian medical device company located in Edmonton, Alberta focused on the commercialization of medical products in the area of embolotherapy. IMB’s mission is to create and commercialize innovative products that treat human disease and improve quality of life.
IMB’s core technology is developed for the treatment of solid malignant tumors and benign tumors or hypertrophic/hyperplastic tissue. Examples include the following:
Solid Malignant Tumors:
Enlarged Prostates Due to Benign Prostatic Hypertrophy/Hyperplasia (BPH)
Over the past 50 years, embolotherapy (therapeutic embolization) has been established as a safe and effective therapy. It has become an integral part of interventional radiology. Embolotherapy is a minimally invasive treatment that selectively prevents blood flow to a target tissue. In addition to malignant and benign tumors, there are applications for trauma management, obesity (gastric artery), vascular malformations, and gastrointestinal bleeding.
IMB’s lead product is Occlusin® 500 Embolization Microspheres, is a first-inclass biodegradable embolic agent that is detectable by ultrasound. The microspheres are delivered through a catheter into the blood vessels that feed a target tissue and selectively block the tissue’s blood supply. The target tissue is either destroyed or devitalized, resulting in a therapeutic benefit. The microspheres slowly degrade and are completely eliminated from the body in 4-6 months. To learn more about Occlusin 500 Embolization Microspheres click here.